Biotechnology

PLBIO

PLBIO released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 1.014 B, actual EPS CNY 0.0626 (forecast EPS CNY 0.3)

PLBIO released FY2025 Annual Earnings on April 28 After-Market (BJT), actual revenue CNY 2.633 B (forecast CNY 3.058 B), actual EPS CNY 0.44 (forecast CNY 0.9153)

PLBIO released FY2026 Q1 earnings on April 28 During-Market (BJT), actual revenue CNY 342.92 M, actual EPS CNY 0.02 (forecast EPS CNY 0.37)

PLBIO to Release FY2025 Earnings on April 29 After-Market (BJT), Forecast Revenue CNY 3.058 B, EPS CNY 0.9153

PLBIO to release FY2026 Q1 earnings report on April 29 During-Market BJT, forecast EPS CNY 0.37

PLBIO released FY2025 Q3 earnings on October 28 After-Market (BJT), actual revenue CNY 631.66 M, actual EPS CNY 0.13 (forecast EPS CNY 0.24)

PLBIO released FY2025 9 Months Earnings on October 28 After-Market (BJT), actual revenue CNY 1.618 B, actual EPS CNY 0.3815

PLBIO to Release FY2025 Q3 Earnings on October 29 After-Market (BJT), Forecast EPS CNY 0.24

PLBIO released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 611.83 M, actual EPS CNY 0.1592 (forecast EPS CNY 0.25)

PLBIO released FY2025 Semi-Annual Earnings on August 21 After-Market (BJT), actual revenue CNY 986.48 M, actual EPS CNY 0.2467

PLBIO to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Pailin Bio Obtains BBB ESG Rating

Shanxi Coal 'Shengbang' Acquires Control of Pingle Bio

China National Biotec Group Plans to Acquire 21.03% of Pailin Biological Shares for 4.6B

China National Biotec Group Intends to Acquire Controlling Stake in Pailin Bio

Perean Bio's Stocks Resumed Trading and Plans to Transfer Control Rights

Pailin Biotech Plans Control Rights Change

PBL announces 2024 annual dividend of RMB3.5 per 10 shares and a bonus of 3 shares

Pingle Bio Responds to Investors on Exporting Medicines to Pakistan and Future Performance Outlook

PlasmaBio Penalized for Internal Control Defects, Shares Plummet

000403

PLBIO announced that its revenue for the third quarter was 632 million yuan, a decrease of 16.23%; net profit was 121 million yuan, a decrease of 43.74%. Revenue for the first three quarters was 1.618 billion yuan, a decrease of 14.40%; net profit was 357 million yuan, a decrease of 34.19%

Zhitong

PLBIO: The net profit for the third quarter was 121 million yuan, a decrease of 43.74%

688185

06185

603392

300142

KaiYuan Securities released a research report indicating that the domestic API (Active Pharmaceutical Ingredient) industry is at the bottom of the cycle, with some companies actively laying out innovative drugs, expected to enter a harvest period. Meanwhile, the blood products industry is accelerating mergers and integrations, with medium to large enterprises expected to undergo mergers and reorganizations in 2025. Affected by policies, the medical services industry faces challenges, but some companies with strong brands and AI layouts are expected to recover first

CanSinoBIO

CANSINOBIO

Wantai Biological

WALVAX

Open Source Securities: API companies accelerate the layout of innovative drugs, and the AI + medical layout is gradually deepening

According to the Zhitong Finance APP, PLBIO released its semi-annual report for 2025, showing that the company's operating revenue was 986 million yuan, a year-on-year decrease of 13.18%. The net profit attributable to shareholders of the listed company was 236 million yuan, a year-on-year decrease of 27.89%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 215 million yuan, a year-on-year decrease of 27.63%. The basic earnings per share were 0.25 yuan

PLBIO released its performance for the first half of the year, with a net profit attributable to the parent company of 236 million yuan, a decrease of 27.89%

600161

First, the major shareholder takes action

Wallstreetcn

BTBP

The Mystery of BTBP "Refusing" PLBIO

BTBP announced the abandonment of the acquisition opportunity for PLBIO, as the blood product business involved in the transaction poses a competitive conflict with its main business. The controlling shareholder China National Biological has formally notified BTBP in writing about this business opportunity based on the commitment letter to avoid competition. In the future, China National Biological will implement the acquisition of PLBIO from the perspective of overall development strategy and will make further commitments regarding the issue of competition after completion

BTBP plans to abandon the acquisition of PLBIO business opportunity

The biopharmaceutical sector saw a short-term surge, with BTBP hitting the daily limit, WanZe Co., Ltd. previously sealing the board, and Eddie Pharmaceuticals, IM Motors, Boya Bio, Bohui Innovation, PLBIO, and others following suit

The biopharmaceutical sector saw a short-term surge, with BTBP hitting the daily limit

01099

PLBIO's controlling stake has been transferred to China National Pharmaceutical Group Co., Ltd., which will take control of PLBIO, with the actual controller changing from Shaanxi State-owned Assets to SINOPHARM. This move may lead to industry competition between Tiantan Biological and PLBIO, with market expectations for the two to integrate. The transaction amount is 3.844 billion yuan, with a transaction price of 24.96 yuan per share, representing a 47% premium over the closing price on June 6. After the integration, the combined revenue is expected to catch up with Shanghai RAAS, enhancing the supply concentration in the blood products industry

- On June 10, 2025, Palin Bio announced the transfer of its 21.03% shares from its controlling shareholder to China Biotechnology, changing its actual controller from Shaanxi State Assets to China National Pharmaceutical Group.  
- This acquisition may lead to the integration of Palin Bio with Tian Tan Bio, potentially reshaping the competitive landscape in the blood products industry, where both companies currently face competition.  
- The deal, valued at 38.44 billion yuan, is expected to enhance market concentration and could allow the combined revenue of the two firms to rival that of Shanghai Raist, the industry leader.

SINOPHARM

GRIFOLS SA

PACIFIC SECURITIES

Shanghai RAAS

WEIGUANG BIOLOGICAL

BOYA BIOLOGY

HUALAN BIOLOGICAL

The Battle of the Blood Kings in China

688180

01877

301080

688428

09969

688331

09995

000661

The biopharmaceutical sector saw a short-term surge, with PLBIO hitting the limit up, followed by RemeGen, CCHT, JUNSHI BIO, ACROBIOSYSTEMS, and INNOCARE rising as well

Junshi Biosciences

JUNSHI BIO

ACROBIOSYSTEMS

InnoCare Pharma

INNOCARE

RemeGen

REMEGEN

CCHT

The biopharmaceutical sector sees a short-term surge, PLBIO hits the limit up

Is the industry leader merging with the fourth player?

PLBIO's ownership change confirmed by China National Biological Group, further concentration of blood products achieves another milestone

PLBIO announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, changing the controlling shareholder to China National Pharmaceutical Group and the actual controller to China National Pharmaceutical Group. The company's stock will resume trading on June 10, 2025

PLBIO: The controlling shareholder plans to change to China National Biological, and the stock will resume trading

PLBIO(000403.SZ)